Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

被引：0

作者：

Karimi, Yasmin H. ^{[1
]}

Thieblemont, Catherine ^{[2
]}

Ghesquieres, Herve ^{[3
]}

Cheah, Chan Y. ^{[4
,5
]}

Clausen, Michael Roost ^{[6
]}

Cunningham, David ^{[7
]}

Jurczak, Wojciech ^{[8
]}

Linton, Kim M. ^{[9
,10
]}

Hutchings, Martin ^{[11
,12
]}

Phillips, Tycel ^{[13
]}

Farooq, Umar ^{[14
]}

Kim, Won Seog ^{[15
]}

Dinh, Minh H. ^{[16
]}

Ghosh, Jagannath ^{[17
]}

Pallai, Rajash ^{[17
]}

Wielgos-Bonvallet, Monica ^{[17
]}

Eskelund, Christian ^{[18
]}

Lugtenburg, Pieternella J. ^{[19
]}

Vose, Julie M. ^{[20
]}

机构：

[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI USA

[2] Univ Paris, APHP, Hop St Louis, Hematooncol, Paris, France

[3] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Pierre Benite, France

[4] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[5] Univ Western Australia, Nedlands, WA, Australia

[6] Vejle Hosp, Vejle, Denmark

[7] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[8] MSC Natl Res Inst Oncol, Krakow, Poland

[9] Univ Manchester, Christie NHS Fdn Trust, Manchester Canc Res Ctr, Manchester, Lancs, England

[10] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[11] Rigshosp, Copenhagen, Denmark

[12] Univ Copenhagen, Copenhagen, Denmark

[13] City Hope Natl Med Ctr, Duarte, CA USA

[14] Univ Iowa, Iowa City, IA USA

[15] Samsung Med Ctr, Seoul, South Korea

[16] AbbVie, N Chicago, IL USA

[17] Genmab, Plainsboro, NJ USA

[18] Genmab, Copenhagen, Denmark

[19] Univ Med Ctr, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[20] Univ Nebraska Med Ctr, Omaha, NE USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

ALL; bispecific; large B-cell lymphoma; hematologic malignancy; non-Hodgkin lymphoma;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-191

引用

页码：S461 / S462

页数：2

共 50 条

[31] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Oluwole, Olalekan O.
Forcade, Edouard
Munoz, Javier
de Guibert, Sophie
Vose, Julie M.
Bartlett, Nancy L.
Lin, Yi
Deol, Abhinav
McSweeney, Peter A.
Goy, Andre H.
Kersten, Marie Jose
Jacobson, Caron A.
Farooq, Umar
Minnema, Monique C.
Thieblemont, Catherine
Timmerman, John
Stiff, Patrick
Avivi, Irit
Tzachanis, Dimitrios
Zheng, Yan
Vardhanabhuti, Saran
Nater, Jenny
Shen, Rhine R.
Miao, Harry
Kim, Jenny
van Meerten, Tom
BLOOD, 2022, 140 : 10399 - 10401
[32] Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis
Li, Yin
Li, Chunfan
Lv, Kebing
Wang, Shixuan
Li, Fei
AMERICAN JOURNAL OF THERAPEUTICS, 2025, 32 (01) : e5 - e16
[33] Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma
Puckrin, Robert
Chua, Neil
Chin, Kelly
Peters, Anthea
Duggan, Peter
Shafey, Mona
Storek, Jan
Jamani, Kareem
Owen, Carolyn
Stewart, Douglas
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (02) : 319 - 325
[34] CheckMate 436: Extended Follow-Up from the Phase 2 Study Investigating Nivolumab Plus Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL)
Zinzani, Pier Luigi
Santoro, Armando
Gritti, Giuseppe
Brice, Pauline
Barr, Paul
Cunningham, David
Kline, Justin
Johnson, Nathalie
Mehta-Shah, Neha
Fanale, Michelle
Francis, Stephen
Moskowitz, Alison
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S398 - S399
[35] Long-term Follow-up from Qualitative Interviews of Patients with Relapsed or Refractory Large B-Cell Lymphoma on Their Treatment Experience While Enrolled in a Lisocabtagene Maraleucel Study
Barba, Pere
Lanar, Sally
Liu, Fei Fei
Eliason, Laurie
Askew, Kshawna
Devlen, Jennifer
Furustrand, Ulrika
Kostic, Ana
BLOOD, 2023, 142
[36] Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)
Abramson, Jeremy S.
Palomba, M. Lia
Gordon, Leo I.
Lunning, Matthew A.
Wang, Michael
Arnason, Jon E.
Purev, Enkhtsetseg
Maloney, David G.
Andreadis, Charalambos
Sehgal, Alison R.
Solomon, Scott R.
Ghosh, Nilanjan
Kostic, Ana
Kim, Yeonhee
Ogasawara, Ken
Dehner, Christine
Siddiqi, Tanya
BLOOD, 2021, 138
[37] Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)
Liebers, Nora
Duell, Johannes
Norenberg, Daniel
Kaebisch, Eva
Kerkhoff, Andrea
Acker, Fabian
Fuhrmann, Stephan
Leng, Corinna
Welslau, Manfred
Chemnitz, Jens
Middeke, Jan Moritz
Weber, Thomas
Trappe, Ralf Ulrich
Pfannes, Roald
Liersch, Ruediger
Spoer, Christian
Gebauer, Niklas
Fuxius, Stefan
Caille, Leandra
Pott, Christiane
Koenecke, Christian
Holtick, Udo
Geer, Thomas
Keller, Ulrich
Claus, Rainer
Mougiakakos, Dimitrios
Mayer, Stephanie
Huttmann, Andreas
Trummer, Arne
Wulf, Gerald
Brunnberg, Uta
Bullinger, Lars
Hess, Georg
Mueller-Tidow, Carsten
Glass, Bertram
Lenz, Georg
Dreger, Peter
Dietrich, Sascha
BLOOD, 2020, 136
[38] Budget Impact Model of Axicabtagene Ciloleucel (Axi-cel) in a US Population of Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL)
Hathway, Joanne
Purdum, Anna
Lin, Vincent W.
Cyr, Philip
Westin, Jason
Jensen, Ivar
BONE MARROW TRANSPLANTATION, 2018, 53 : 878 - 879
[39] Long-term follow-up of paclitaxel and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma
Suh, G. K.
McLaughlin, P.
Romaguera, J. E.
Hagemeister, F. B.
Pro, B.
Khouri, I. F.
Samaniego, F.
Rodriguez, M. A.
Fayad, L. E.
Feng, L.
Younes, A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[40] Long-term follow-up of taxol and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma
Suh, G.
Khouri, I.
McLaughlin, P.
Romaguera, J.
Hagemeister, F.
Pro, B.
Samaniego, F.
Rodriguez, M.
Fayad, L.
Feng, L.
Younes, A.
ANNALS OF ONCOLOGY, 2008, 19 : 149 - 149

← 1 2 3 4 5 →